FDA issues 5-year plan to make its Sentinel system more robust

January 11, 2019


The Food and Drug Administration wants to ensure that its post-market monitoring of drugs and biologics keeps pace with changing drug development and safety ecosystems.

Towards that end, the agency has developed a five-year strategy to grow the capabilities of its Sentinel system by 2023 into a “transformative, multi-purpose national data and scientific resource center for evidence generation that a wide array of stakeholders use to inform all aspects of healthcare decisionmaking.”

Read More on Health Data Management